Antisense nucleic acid compound targeted to VEGF

An antisense nucleic acid compound consisting of a nucleotide sequence complementary to at least 10 contiguous nucleotides in the nucleic acid sequence defined by any of SEQ ID NOS:

• 4, 6, 7, or 8;
• wherein said antisense nucleic acid compound inhibits the expression of vascular endothelial growth factor.

An antisense nucleic acid compound consisting of at least 10 contiguous nucleotides having nine or more nucleotides complementary to, and one nucleotide mismatched to, the nucleic acid sequence defined by any of SEQ ID NOS:

• 2, 3, 4, 5, 6, 7, 8, or 9, and which inhibits the expression of vascular endothelial growth factor.

An antisense nucleic acid compound consisting of 12 or more contiguous nucleotides having 11 or more nucleotides complementary to, and 1 nucleotide mismatched to, the nucleic acid sequence defined by any of SEQ ID NOS:

• 2, 3, 4, 5, 6, 7, 8, or 9, and which inhibits the expression of vascular endothelial growth factor.

An antisense nucleic acid compound which inhibits the expression of vascular endothelial growth factor and which consists of a nucleic acid sequence selected from the group consisting of SEQ ID NOS:

• 15, 23, 24, 25, 26, 29, 30, 31, 32, 37, 41, 42, 43, 46, 47, 49, 50, 51, 57, 58, 59, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 90, 99, 100, 101, 102, 103, 110, 111, 112, 114, 117, 118, 119, 120, 121, 123, 124, 125, 128, 129, 130, 131, 132, 134, 135, 136, 137, 138, 139, 141, 146, 147, 148, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 167, 169, 170, 171, 172, 173, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184 185, and combinations thereof.

An antisense nucleic acid compound which includes the expression of vascular endothelial growth factor to a level of about 10% or less and which consists of a nucleic acid sequence selected from the group consisting of GCTCTATC and CTCTCTCTT.

An antisense nucleic acid compound consisting of a nucleotide sequence complementary to a nucleic acid sequence defined by any of SEQ ID NOS:

• 2, 3, 4, 5, 6, 7, 8 or 9 wherein said antisense nucleic acid compound inhibits the expression of vascular endothelial growth factor.

An antisense nucleic acid compound which inhibits the expression of vascular endothelial growth factor and which consists of a nucleic acid sequence selected from the group consisting of SEQ ID NOS:

• 13, 17, 18, 19, 20, 21, 22, 27, 33, 34, 35, 36, 38, 39, 40, 44, 45, 48, 49, 52, 53, 56, 60, 61, 62, 87, 89, 92, 95, 97, 98, 104, 105, 106, 107, 108, 115, 116, 122, 126, 127, 140, 142, 144, 145, 149, 150, 151, 152, 174, and combinations thereof.

An antisense nucleic acid compound consisting of a nucleotide sequence complementary to 8 to 10 contiguous nucleotides in the nucleic acid sequence defined by any of SEQ ID NOS:

• 2, 3, 5, or 9;
• wherein said antisense nucleic acid compound inhibits the expression of vascular endothelial growth factor.

An antisense nucleic acid compound consisting of a nucleotide sequence complementary to 10 to 12 contiguous nucleotides in the nucleic acid sequence defined by any of SEQ ID NOS:

• 2, 3, 5, or 9;
• wherein said antisense nucleic acid compound inhibits the expression of vascular endothelial growth factor.

An antisense nucleic acid compound consisting of a nucleotide sequence complementary to at least 8 contiguous nucleotides in the nucleic acid sequence defined by any of SEQ ID NOS:

• 2, 3, 5, or 9;
• wherein said antisense nucleic acid compound inhibits the expression of vascular endothelial growth factor.

An antisense nucleic acid compound consisting of a nucleotide sequence complementary to at least 10 contiguous nucleotides in the nucleic acid sequence defined by any of SEQ ID NOS:

• 2, 3, 5, or 9;
• wherein said antisense nucleic acid compound inhibits the expression of vascular endothelial growth factor.

A method of inhibiting the expression of a vascular endothelial growth factor, comprising administering to a subject an antisense nucleic acid compound consisting of a nucleotide sequence complementary to at least 8 contiguous nucleotides in the nucleic acid sequence defined by any of SEQ ID NOS:

• 4, 6, 7, or 8;
• in a physiologically acceptable carrier, diluent, or excipient thereby inhibiting the expression of the vascular endothelial growth factor.

A method of inhibiting the expression of a vascular endothelial growth factor, comprising administering to a subject an antisense nucleic acid compound consisting of a nucleotide sequence complementary to at least 10 contiguous nucleotides in the nucleic acid sequence defined by any of SEQ ID NOS:

• 4, 6, 7, or 8;
• in a physiologically acceptable carrier, diluent, or excipient thereby inhibiting the expression of the vascular endothelial growth factor.

A method of inhibiting the expression of a vascular endothelial growth factor, comprising administering to a subject an antisense nucleic acid compound consisting of a nucleotide sequence complementary to 8 to 10 contiguous nucleotides in the nucleic acid sequence defined by any of SEQ ID NOS:

• 2, 3, 5, or 9, in a physiologically acceptable carrier, diluent, or excipient thereby inhibiting the expression of the vascular endothelial growth factor.

A method of inhibiting the expression of a vascular endothelial growth factor, comprising administering to a subject an antisense nucleic acid compound consisting of a nucleotide sequence complementary to 10 to 12 contiguous nucleotides in the nucleic acid sequence defined by any of SEQ ID NOS:

• 2, 3, 5, or 9, in a physiologically acceptable carrier, diluent or excipient thereby inhibiting the expression of the vascular endothelial growth factor.

A method of inhibiting the expression of a vascular endothelial growth factor, comprising administering to a subject an antisense nucleic acid compound consisting of a nucleotide sequence complementary to at least 8 contiguous nucleotides in the nucleic acid sequence defined by any of SEQ ID NOS:

• 2, 3, 5, or 9, in a physiologically acceptable carrier, diluent, or excipient thereby inhibiting the expression of the vascular endothelial growth factor.

A method of inhibiting the expression of a vascular endothelial growth factor, comprising administering to a subject an antisense nucleic acid compound consisting of a nucleotide sequence complementary to at least 10 contiguous nucleotides in the nucleic acid sequence defined by any of SEQ ID NOS:

• 2, 3, 5, or 9, in a physiologically acceptable carrier, diluent, or excipient thereby inhibiting the expression of the vascular endothelial growth factor.